JPMorgan Chase & Co. Has $4.46 Million Stock Holdings in 4D Molecular Therapeutics, Inc. $FDMT

JPMorgan Chase & Co. trimmed its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 42.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 513,515 shares of the company’s stock after selling 374,501 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.90% of 4D Molecular Therapeutics worth $4,462,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. AQR Capital Management LLC bought a new position in shares of 4D Molecular Therapeutics in the 1st quarter valued at about $46,000. Millennium Management LLC raised its holdings in shares of 4D Molecular Therapeutics by 15.0% in the 1st quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock valued at $5,278,000 after purchasing an additional 213,264 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in 4D Molecular Therapeutics in the 1st quarter valued at about $39,000. American Century Companies Inc. grew its holdings in 4D Molecular Therapeutics by 11.5% during the second quarter. American Century Companies Inc. now owns 48,810 shares of the company’s stock worth $181,000 after purchasing an additional 5,026 shares during the period. Finally, XTX Topco Ltd bought a new position in 4D Molecular Therapeutics during the second quarter worth about $292,000. 99.27% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have issued reports on the company. Barclays assumed coverage on 4D Molecular Therapeutics in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $33.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 21st. Royal Bank Of Canada boosted their target price on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an “outperform” rating in a report on Thursday, March 19th. Wall Street Zen raised 4D Molecular Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Finally, Chardan Capital reaffirmed a “buy” rating and set a $26.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday, March 19th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $31.25.

4D Molecular Therapeutics Stock Performance

NASDAQ:FDMT opened at $9.48 on Friday. 4D Molecular Therapeutics, Inc. has a 52 week low of $2.23 and a 52 week high of $12.34. The firm’s 50-day simple moving average is $9.05 and its 200 day simple moving average is $9.27. The firm has a market cap of $483.95 million, a price-to-earnings ratio of -3.92 and a beta of 2.94.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings data on Wednesday, March 18th. The company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.96. 4D Molecular Therapeutics had a negative net margin of 164.43% and a negative return on equity of 31.75%. The firm had revenue of $85.09 million during the quarter, compared to the consensus estimate of $30.86 million. Sell-side analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.